芍药甘草汤与紫杉醇合用以预防化疗后疼痛的副反应。但是，芍药甘草汤对紫杉醇的药动学影响的研究，迄今国内外尚无报道。我们的前期研究发现芍药甘草汤导致紫杉醇的药动学显著变化；白芍和甘草配伍影响其效应成分的药动学。文献表明，甘草提取物能够激活核受体PXR，从而诱导药物代谢酶以及药物转运体蛋白的表达；CYP3A4以及P-糖蛋白的功能改变是导致紫杉醇血药浓度发生变化的主要原因之一。因此，我们推测芍药甘草汤对紫杉醇药动学的影响可能是通过芍药甘草汤-PXR-CYP3A4/MDRl途径介导，而方中白芍和甘草配伍对这一过程起协同作用。本项目应用UPLC、双荧光报告基因平台、质粒转染和RT-PCR等技术，从体内和体外两个层次，观察芍药甘草汤及其拆方对紫杉醇药动学的影响并研究其作用机制，探讨中药复方配伍在这一过程中的作用。本课题将从新的视角为中西药结合治疗肿瘤的合理用药提供理论依据。

Shaoyao-Gancao-Tang (SGT) is administered in combination with paclitaxel to prevent the pain induced by chemotherapy. But until now, it has not been clari?ed whether there are any pharmacokinetic interactions between SGT and paclitaxel. Our preliminary research revealed that pharmacokinetic parameters of paclitaxel were significantly altered with SGT. Compatibility of Radix paeoniae alba and Radix Glycyrrhizae influenced effective compounds' pharmacokinetics. Data show that extract of Radix Glycyrrhizae can activate the nuclear receptor PXR and then induce expression of drug metabolism enzyme and drug transporter protein. The variance of the CYP3A4 and P-gp activity is the plausible explanation for the changed blood concentration of paclitaxel. So, we hypothesize that the signal pathway of SGT-PXR-CYP3A4/MDRl may result in the interaction between SGT and paclitaxel, and compatibility of Radix paeoniae alba and Radix Glycyrrhizae has a synergism effect in the process. The present study will observe the effect of SGT and its single herb decoction on the pharmacokinetics of paclitaxel, aim to approach the mechanism and explore the role of compatibility of Chinese compound medicine by techniques such as UPLC，double fluorescent reporter genes platform，plasmid transfection，RT-PCR. The results would be helpful to apply a theoretical basis for combination of Chinese traditional and western medicine treatment of tumors of the rational use of drugs from a new viewpoint.